Quick Answer
Immunovant, Inc. reported Stockholders Equity of $707.45 million for the year ending 2025.
- Immunovant, Inc. showed an increase of +14.5% in Stockholders Equity from 2024 to 2025.
- This data is from Immunovant, Inc.'s annual report (Form 10-K), filed with the SEC on May 29, 2025.
- XBRL data for this metric is available from 2018 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $2.32 million | Q4 2018: $7.96 million | Q2 2019: -$12.11 million | Q3 2019: -$23.28 million | Q4 2019: $111.86 million | Q2 2020: $267.78 million | Q3 2020: $438.41 million | Q4 2020: $414.15 million | Q2 2021: $365.53 million | Q3 2021: $536.40 million | Q4 2021: $505.15 million | Q2 2022: $436.49 million | Q3 2022: $395.75 million | Q4 2022: $414.68 million | Q2 2023: $299.87 million | Q3 2023: $251.81 million | Q4 2023: $679.34 million | Q1 2024: $617.76 million | Q2 2024: $544.66 million | Q3 2024: $449.05 million | Q4 2024: $352.62 million | Q1 2025: $707.45 million | Q2 2025: $608.54 million | Q3 2025: $519.71 million | Q4 2025: $986.14 million.
- Over the full 9 years of available data (2018 to 2025), Immunovant, Inc.'s Stockholders Equity has grown by 47,357.6%.
- Historical annual values: Fiscal year 2025: $707.45 million | Fiscal year 2024: $617.76 million | Fiscal year 2023: $362.49 million | Fiscal year 2022: $469.83 million | Fiscal year 2021: $391.48 million | Fiscal year 2020: $94.07 million | Fiscal year 2019: $7.34 million | Fiscal year 2018: -$411.0 thousand | Fiscal year 2018: -$1.50 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: